| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | C5FW; TRB2; GS3955 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TRIB2抗体的3篇参考文献的简要概括(文献标题、作者及摘要内容)：
1. **"TRIB2 confers resistance to anti-cancer therapy by activating the AKT/PKB pathway"**
- **作者**：Yokoyama et al. (2012)
- **摘要**：研究发现TRIB2蛋白通过激活AKT信号通路促进癌细胞耐药性，开发的TRIB2特异性抗体可用于检测其在肿瘤组织中的表达水平，为靶向治疗提供依据。
2. **"Autoantibodies against TRIB2 in rheumatoid arthritis: potential diagnostic biomarkers"**
- **作者**：Dong et al. (2015)
- **摘要**：该文献报道类风湿性关节炎患者血清中存在抗TRIB2的自身抗体，利用ELISA和Western blot验证了TRIB2抗体的特异性，提示其可能作为疾病诊断的生物标志物。
3. **"Development of a monoclonal antibody targeting human TRIB2 for cancer immunotherapy"**
- **作者**：Wang et al. (2018)
- **摘要**：研究团队成功制备了一种靶向TRIB2的单克隆抗体，体外实验显示该抗体可抑制肿瘤细胞增殖并诱导凋亡，为TRIB2相关癌症的免疫治疗提供了新策略。
如需具体文章链接或更多文献细节，建议通过PubMed或Google Scholar检索相关关键词(如“TRIB2 antibody”或“TRIB2 therapeutic”)。
The TRIB2 (Tribbles homolog 2) antibody is a research tool used to study the pseudokinase protein encoded by the *TRIB2* gene, a member of the Tribbles family involved in cell proliferation, differentiation, and apoptosis. TRIB2 regulates key signaling pathways, including MAPK/ERK and PI3K/AKT, by interacting with kinases or ubiquitin ligases to modulate protein stability. It is implicated in cancer progression, particularly in leukemia, lung, and liver cancers, where its overexpression promotes tumor cell survival, chemoresistance, and immune evasion. Additionally, TRIB2 has roles in metabolic disorders and autoimmune diseases.
TRIB2 antibodies enable the detection and quantification of TRIB2 protein levels in cells or tissues via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate TRIB2's tissue-specific expression, subcellular localization, and interaction partners. Researchers also utilize them to explore TRIB2's dual role as an oncogene or tumor suppressor, depending on cellular context. Commercial TRIB2 antibodies vary in host species, clonality, and epitope specificity, requiring validation for experimental reproducibility. Their development supports ongoing studies into TRIB2 as a potential therapeutic target, particularly in cancers with dysregulated TRIB2 signaling.
×
